ArticleTechnology in cancer research & treatment
miR-342-3p Regulates the Proliferation and Apoptosis of NSCLC Cells by Targeting
Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Multi-Institutional Integration of Circulating miRNAs and Protein Tumor Markers for Early Lung Cancer Detection.JTO clinical and research reports · 2026Article
- Tick lipocalin triggers mammalian IGFBP-3-mediated apoptosis in macrophages and keratinocytes.Frontiers in immunology · 2026Article
- Intronic miR-342 is a key regulator of cellular glycolysis in Foxp3+ regulatory CD4 T cells.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- 7‑Difluoromethoxyl‑5,4'‑di‑n‑octylygenistein targets the STAT3 pathway by upregulating microRNA‑152‑3p expression to inhibit self‑renewal and tumor growth in non‑small cell lung carcinoma.Oncology reports · 2025Article
- Martini compatible coarse-grained model of polyethylenimine for pulmonary gene delivery.Scientific reports · 2025Article
- Inhibitory effect of miR342 on the progression of triple-negative breast cancer cells in vitro and in the mice model.BioImpacts : BI · 2024Article
- Review
- MicroRNAs in tear fluids predict underlying molecular changes associated with Alzheimer's disease.Life science alliance · 2023Article
- Development of a 5-FU modified miR-129 mimic as a therapeutic for non-small cell lung cancer.Molecular therapy oncolytics · 2023Article
- The role of microRNAs in neurobiology and pathophysiology of the hippocampus.Frontiers in molecular neuroscience · 2023Review
- [Expression of miR-342-3p in rheumatoid arthritis patients and its effect on synovial fibroblast inflammation and migration].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- IgG from Adult Atopic Dermatitis (AD) Patients Induces Thymic IL-22 Production and CLA Expression on CD4+ T Cells: Possible Epigenetic Implications Mediated by miRNA.International journal of molecular sciences · 2022Article
- MicroRNA Profile Alterations in Parathyroid Carcinoma: Latest Updates and Perspectives.Cancers · 2022Review
- The Role of miRNA in Tumor Immune Escape and miRNA-Based Therapeutic Strategies.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
microRNA-342-3p plays an important role in tumor occurrence and development. However, the expression pattern and roles of microRNA-342-3p in nonsmall cell lung cancer remain poorly understood. In the current study, we explored the roles and underlying mechanisms of microRNA-342-3p in nonsmall cell lung cancer via gain- and loss-of-function analyses. We used quantitative reverse-transcription-polymerase chain reaction and western blotting assays to measure the expression levels of microRNA-342-3p in nonsmall-cell lung cancer and B-cell lymphoma-2. Furthermore, we used small interfering RNA and RNA mimics to analyze the functions and underlying mechanisms of microRNA-342-3p in nonsmall cell lung cancer cells. A luciferase reporter assay was performed to evaluate the direct binding site of the 5'-untranslated region of B-cell lymphoma-2 targeted by microRNA-342-3p. We found that the expression of microRNA-342-3p was significantly lower in nonsmall cell lung cancer cells and tissues than in normal cells and tissues. The upregulation of microRNA-342-3p suppressed cell proliferation while promoting apoptosis in H1975, H460, and H226 cells. The overexpression of microRNA-342-3p in nonsmall cell lung cancer cells led to the downregulation of mRNA and protein levels in B-cell lymphoma-2 cells. Thus, B-cell lymphoma-2 was identified as a direct target of microRNA-342-3p. These findings indicate that microRNA-342-3p inhibits the growth of nonsmall cell lung cancer by repressing the expression of B-cell lymphoma-2, which suggests that microRNA-342-3p could be a potential target for the treatment of nonsmall cell lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.